
Nova Mentis (OTC: NMLSF) to Produce Psilocybin Capsules for Phase 2A Clinical Study
Manufacturing Contract with the Toronto Institute of Pharmaceutical Technology VANCOUVER, BC, April 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]